Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability

Bibliography

• Kerckhove N, Collin A, Condé S. Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol. 2017;8:86.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Kyritsis AP, Makatsoris T, et al. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res. 2014;6:135–147.
   PubMed Web of Science ®Google Scholar
• Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. Cancer J Clin. 2013;63:419–437.
   PubMed Web of Science ®Google Scholar
• Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol. 2009;8:654–667.
   PubMed Web of Science ®Google Scholar
• Barreto LC, Oliveira FS, Nunes PS, et al. Epidemiologic study of Charcot-Marie-Tooth Disease: a systematic review. Neuroepidemiology. 2016;46:157–165.
   PubMed Web of Science ®Google Scholar
• Saporta MA. Charcot-Marie-Tooth disease and other inherited neuropathies. Continuum (Minneap Minn). 2014;20:1208–1225.
   PubMedGoogle Scholar
• Murphy SM, Laura M, Fawcett K, et al. Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. J Neurol Neurosurg Psychiatry. 2012;83:706–710.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Cornblath DR, Merkies ISJ, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol. 2013;24:454–462.
   PubMed Web of Science ®Google Scholar
• Weiden PL, Wright SE. Vincristine neurotoxicity. N Engl J Med. 1972;286:1369–1370.
   PubMed Web of Science ®Google Scholar
• McGuire SA, Gospe SM, Dahl G. Acute vincristine neurotoxicity in the presence of hereditary motor and sensory neuropathy type I. Med Pediatr Oncol. 1989;17:520–523.
   PubMedGoogle Scholar
• Dickerhoff R. Severe vincristine neurotoxicity in a patient with Charcot-Marie-Tooth disease. Pediatr Hematol Oncol. 1988;5:61–64.
   PubMed Web of Science ®Google Scholar
• Griffiths JD, Stark RJ, Ding JC, et al. Vincristine neurotoxicity in Charcot-Marie-Tooth syndrome. Med J Aust. 1985;143:305–306.
   PubMed Web of Science ®Google Scholar
• Chauncey TR, Showel JL, Fox JH. Vincristine neurotoxicity. JAMA. 1985;254:507.
   PubMed Web of Science ®Google Scholar
• Hogan-Dann CM, Fellmeth WG, McGuire SA, et al. Polyneuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome. JAMA. 1984;252:2862–2863.
   PubMed Web of Science ®Google Scholar
• Graf WD, Chance PF, Lensch MW, et al. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer. 1996;77:1356–1362.
   PubMed Web of Science ®Google Scholar
• Trobaugh-Lotrario AD, Smith AA, Odom LF. Vincristine neurotoxicity in the presence of hereditary neuropathy. Med Pediatr Oncol. 2003;40:39–43.
   PubMedGoogle Scholar
• Naumann R, Mohm J, Reuner U, et al. Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity. Br J Haematol. 2001;115:323–325.
   PubMed Web of Science ®Google Scholar
• Hildebrandt G, Holler E, Woenkhaus M, et al. Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy. Ann Oncol. 2000;11:743–747.
   PubMed Web of Science ®Google Scholar
• Mercuri E, Poulton J, Buck J, et al. Vincristine treatment revealing asymptomatic hereditary motor sensory neuropathy type 1A. Arch Dis Child. 1999;81:442–443.
   PubMed Web of Science ®Google Scholar
• Uno S, Katayama K, Dobashi N, et al. Acute vincristine neurotoxicity in a non-Hodgkin’s lymphoma patient with Charcot-Marie-Tooth disease. Rinsho Ketsueki. 1999;40:414–419.
   PubMedGoogle Scholar
• Olek MJ, Bordeaux B, Leshner RT. Charcot-Marie-Tooth disease type I diagnosed in a 5-year-old boy after vincristine neurotoxicity, resulting in maternal diagnosis. J Am Osteopath Assoc. 1999;99:165–167.
   PubMedGoogle Scholar
• Neumann Y, Toren A, Rechavi G, et al. Vincristine treatment triggering the expression of asymptomatic Charcot-Marie-Tooth disease. Med Pediatr Oncol. 1996;26:280–283.
   PubMedGoogle Scholar
• Chauvenet AR, Shashi V, Selsky C, et al. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a pediatric oncology group study. J Pediatr Hematol Oncol. 2003;25:316–320.
   PubMed Web of Science ®Google Scholar
• Orejana-García AM, Pascual-Huerta J, Pérez-Melero A. Charcot-Marie-Tooth disease and vincristine. J Am Pediatr Med Assoc. 2003;93:229–233.
   PubMed Web of Science ®Google Scholar
• Igarashi M, Thompson EI, Rivera GK. Vincristine neuropathy in type I and type II Charcot-Marie-Tooth disease (hereditary motor sensory neuropathy). Med Pediatr Oncol. 1995;25:113–116.
   PubMedGoogle Scholar
• Geny C, Gaio JM, Mallaret M, et al. Charcot-Marie-Tooth disease disclosed by a treatment with vincristine in familial Hodgkin’s disease. Ann Med Interne (Paris). 1990;141:709–710.
   PubMedGoogle Scholar
• Schiavetti A, Frascarelli M, Uccini S, et al. Vincristine neuropathy: neurophysiological and genetic studies in a case of Wilms tumor. Pediatr Blood Cancer. 2004;43:606–609.
   PubMed Web of Science ®Google Scholar
• Chaudhry V, Chaudhry M, Crawford TO, et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology. 2003;60:337–340.
   PubMed Web of Science ®Google Scholar
• Cil T, Altintas A, Tamam Y, et al. Low dose vincristine-induced severe polyneuropathy in a Hodgkin lymphoma patient: a case report (vincristine-induced severe polyneuropathy). J Pediatr Hematol Oncol. 2009;31:787–789.
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Kawakami K, Kumamoto T, et al. Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2008;30:519–521.
   PubMed Web of Science ®Google Scholar
• Porter CC, Carver AE, Albano EA. Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X. Pediatr Blood Cancer. 2009;52:298–300.
   PubMed Web of Science ®Google Scholar
• Ichikawa M, Suzuki D, Inamoto J, et al. Successful alternative treatment containing vindesine for acute lymphoblastic leukemia with Charcot-Marie-Tooth disease. J Pediatr Hematol Oncol. 2012;34:239–241.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Hashiguchi A, Suzuki S, et al. Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel EGR2 mutation. Neurogenetics. 2012;13:77–82.
   PubMed Web of Science ®Google Scholar
• Ajitsaria R, Reilly M, Anderson J. Uneventful administration of vincristine in Charcot-Marie-Tooth disease type 1X. Pediatr Blood Cancer. 2008;50:874–876.
   PubMed Web of Science ®Google Scholar
• Martino MA, Miller E, Grendys EC. The administration of chemotherapy in a patient with Charcot-Marie-Tooth and ovarian cancer. Gynecol Oncol. 2005;97:710–712.
   PubMed Web of Science ®Google Scholar
• Yerushalmi R, Levi I, Wygoda M, et al. Are platinum-based chemotherapeutic drugs safe for patients with Charcot-Marie-Tooth disease?. J Peripher Nerv Syst. 2007;12:139–141.
   PubMed Web of Science ®Google Scholar
• Cowie F, Barrett A. Uneventfull administration of cisplatin to a man with X-linked Charcot-Marie-Tooth disease (CMT). Ann Oncol. 2001;12:421–422.
   PubMed Web of Science ®Google Scholar
• Aghajan Y, Yoon JM, Crawford JR. Severe vincristine-induced polyneuropathy in a teenager with anaplastic medulloblastoma and undiagnosed Charcot-Marie-Tooth disease. BMJ Case Rep. 2017;2017:pii: bcr-2016-218981.
   Google Scholar
• Weimer LH, Podwall D. Medication-induced exacerbation of neuropathy in Charcot Marie Tooth Disease. J Neurol Sci. 2006;242:47–54.
   PubMed Web of Science ®Google Scholar
• Beutler AS, Kulkarni AA, Kanwar R, et al. Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy. Ann Neurol. 2014;76:727–737.
   PubMed Web of Science ®Google Scholar
• Schneider BP, Lai D, Shen F, et al. Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans. Oncotarget. 2016;7:82244–82253.
   PubMed Web of Science ®Google Scholar